Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancerReportar como inadecuado


Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancer


Targeted use of camptothecin as a specific pharmacological agent for the treatment of triple negative breast cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Abstract

Triple negative breast cancer TNBC accounts for 15 to 20% of all new breast cancers diagnosed in the United States. This figure increases to greater than 30% in minority populations. Currently, targeted therapeutic options are not available for TNBC, thus resulting in the use of general chemotherapeutics and lower survival rates for those afflicted with the disease. Camptothecin and its structural analogues CPTs are specific, reversible inhibitors of topoisomerase I topoi, and have recently shown promise in the treatment ofTNBC, with a response rate of nearly 40%. CPTs are targeted drugs, but only effective within a subset of cancer patient populations. In order to understand the regulation of topoi upon CPT administration and elucidate the resistance mechanism, we isolated a topoi interacting protein complex. We further investigated the role of proteins associated with topoi, and have determined that: I following CPT administration, topoi is phosphorylated at serine 10 S10 by the DNA-PK-Ku-70-Ku-80 complex, II S10 phosphorylation ensures the ubiquitination oftopoi by the BRCA1-BARD1 heterodimer, Ill topoi is subsequently degraded by the ubiquitin-proteasomal pathway UPP, and IV the rate oftopoi degradation determines the cellular response to CPT. In summary, BRCA1-BARD1 E3 ligase activity leads to the ubiquitination and rapid degradation of to poi, conferring cellular resistance to CPT. Phosphorylation levels of S10 on topol correlates to the rate of topol degradation, thus can be used as a predictive biomarker for CPT response. Taken together, CPT can be an effective treatment for a subset of the TNBC patient population.

Boston University Theses and Dissertations -



Autor: Shah, Ankur K. - -

Fuente: https://open.bu.edu/



DESCARGAR PDF




Documentos relacionados